Oncotarget

Research Papers:

Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells

Stefano Volinia _, Valeria Bertagnolo, Silvia Grassilli, Federica Brugnoli, Marco Manfrini, Marco Galasso, Cristian Scatena, Chiara Maria Mazzanti, Francesca Lessi, Giuseppe Naccarato, Adelaide Caligo, Enzo Bianchini, Quirino Piubello, Enrico Orvieto, Massimo Rugge, Cristina Natali, Domenico Reale, Andrea Vecchione, Sarah Warner, Carlo Maria Croce and Silvano Capitani

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:23543-23553. https://doi.org/10.18632/oncotarget.25261

Metrics: PDF 662 views  |   HTML 1019 views  |   ?  


Abstract

Stefano Volinia1,2,*, Valeria Bertagnolo1,*, Silvia Grassilli1, Federica Brugnoli1, Marco Manfrini1, Marco Galasso1, Cristian Scatena3, Chiara Maria Mazzanti4, Francesca Lessi4, Giuseppe Naccarato3, Adelaide Caligo3, Enzo Bianchini5, Quirino Piubello6, Enrico Orvieto7, Massimo Rugge7, Cristina Natali8, Domenico Reale8, Andrea Vecchione9, Sarah Warner10, Carlo Maria Croce10 and Silvano Capitani1,2

1Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44121, Italy

2LTTA Centre, University of Ferrara, Ferrara 44121, Italy

3Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa 56126, Italy

4Pisa Science Foundation, Pisa 56121, Italy

5Pathology Division, S. Anna University Hospital, Ferrara 44124, Italy

6Department of Diagnostic and Pathology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona 37126, Italy

7Department of Medicine DIMED, University of Padova, Padova 35121, Italy

8Pathology Division, Santa Maria della Misericordia Hospital, Rovigo 45100, Italy

9Department of Pathology, St. Andrea University Hospital, University of Rome, La Sapienza, Rome 00185, Italy

10Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA

*These authors contributed equally to this work

Correspondence to:

Stefano Volinia, email: s.volinia@unife.it

Valeria Bertagnolo, email: bgv@unife.it

Keywords: DCIS; breast tumor progression; EMT; breast cancer; over-diagnosis

Received: November 28, 2017     Accepted: April 06, 2018     Published: May 04, 2018

ABSTRACT

A substantial number of ductal carcinoma in situ (DCIS) detected by mammography never progress to invasive ductal carcinoma (IDC) and current approaches fail to identify low-risk patients not at need of adjuvant therapies. We aimed to identify the key miRNAs protecting DCIS from malignant evolution, that may constitute markers for non-invasive lesions.

We studied 100 archived DCIS samples, including pure DCIS, DCIS with adjacent IDC and pure DCIS from patients with subsequent IDC in contralateral breast or no recurrence. A DCIS derived cell line was used for molecular and cellular studies.

A genome wide study revealed that pure DCIS has higher miR-126 and miR-218 expression than DCIS with adjacent IDC lesions or than IDC. The down-regulation of miR-126 and miR-218 promoted invasiveness in vitro and, in patients with pure DCIS, was associated with later onset of IDC. Survival studies of independent cohorts indicated that both miRNAs play a protective role in IDC. The clinical findings are in agreement with the miRNAs’ roles in cell adhesion, differentiation and proliferation.

We propose that miR-126 and miR-218 have a protective role in DCIS and represent novel biomarkers for the risk assessment in women with early detection of breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25261